Niox Group PLC
LSE:NIOX

Watchlist Manager
Niox Group PLC Logo
Niox Group PLC
LSE:NIOX
Watchlist
Price: 65.6 GBX -3.53%
Market Cap: 274.1m GBX

Niox Group PLC
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Niox Group PLC
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Niox Group PLC
LSE:NIOX
Free Cash Flow
ÂŁ16.7m
CAGR 3-Years
86%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Free Cash Flow
-$142.1m
CAGR 3-Years
-2%
CAGR 5-Years
-89%
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Free Cash Flow
-$306.1m
CAGR 3-Years
-37%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Free Cash Flow
ÂŁ20.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Free Cash Flow
ÂŁ48.6m
CAGR 3-Years
N/A
CAGR 5-Years
10%
CAGR 10-Years
9%
Oxford BioMedica PLC
LSE:OXB
Free Cash Flow
-ÂŁ12m
CAGR 3-Years
29%
CAGR 5-Years
11%
CAGR 10-Years
5%
No Stocks Found

Niox Group PLC
Glance View

Market Cap
274m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.

NIOX Intrinsic Value
50.86 GBX
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Niox Group PLC's Free Cash Flow?
Free Cash Flow
16.7m GBP

Based on the financial report for Jun 30, 2025, Niox Group PLC's Free Cash Flow amounts to 16.7m GBP.

What is Niox Group PLC's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
86%

Over the last year, the Free Cash Flow growth was 39%. The average annual Free Cash Flow growth rates for Niox Group PLC have been 86% over the past three years .

Back to Top